These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3035879)

  • 21. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.
    Pak CY; Sakhaee K; Zerwekh JE; Parcel C; Peterson R; Johnson K
    J Clin Endocrinol Metab; 1989 Jan; 68(1):150-9. PubMed ID: 2909549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1,25(OH)2D3 and renal function. A controlled clinical study in normal elderly women.
    Jensen GF; Christiansen C; Transbøl I
    Acta Med Scand; 1982; 211(1-2):51-4. PubMed ID: 7041522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
    Karaplis AC; Chouha F; Djandji M; Sampalis JS; Hanley DA
    Ann Pharmacother; 2011 May; 45(5):561-8. PubMed ID: 21521859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of vitamin D3 and its metabolites 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol on callus mineralization in rats with femoral fracture].
    Blazhevich NV; Sergeev IN; Arkhapchev IuP; Isaeva VA; Spirichev VB
    Vopr Med Khim; 1982; 28(6):98-105. PubMed ID: 6297167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis.
    Zerwekh JE; Sakhaee K; Pak CY
    J Clin Endocrinol Metab; 1985 Mar; 60(3):615-7. PubMed ID: 3871787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local action of oral 1,25-dihydroxycholecalciferol on calcium absorption in osteoporosis.
    Francis RM; Peacock M
    Am J Clin Nutr; 1987 Aug; 46(2):315-8. PubMed ID: 3618534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
    Jones G; Hogan DB; Yendt E; Hanley DA
    CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
    Wagner D; Amrein K; Dimai HP; Kniepeiss D; Tscheliessnigg KH; Kornprat P; Dobnig H; Pieber T; Fahrleitner-Pammer A
    Transplantation; 2012 Feb; 93(3):331-6. PubMed ID: 22217531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of estrogen/gestagen and 24R,25-dihydroxyvitamin D3 therapy on bone formation in postmenopausal women.
    Thomsen K; Riis B; Christiansen C
    J Bone Miner Res; 1986 Dec; 1(6):503-7. PubMed ID: 3332556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial.
    Bang UC; Kolte L; Hitz M; Schierbeck LL; Nielsen SD; Benfield T; Jensen JE
    AIDS Res Hum Retroviruses; 2013 Apr; 29(4):658-64. PubMed ID: 23199009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year changes in mandibular bone mass in an osteoporotic population.
    Kribbs PJ
    J Prosthet Dent; 1992 May; 67(5):653-5. PubMed ID: 1527749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone-forming ability of 24R,25-dihydroxyvitamin D3 in the hypophosphatemic mouse.
    Yamate T; Tanaka H; Nagai Y; Yamato H; Taniguchi N; Nakamura T; Seino Y
    J Bone Miner Res; 1994 Dec; 9(12):1967-74. PubMed ID: 7872063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.
    Riggs BL; Seeman E; Hodgson SF; Taves DR; O'Fallon WM
    N Engl J Med; 1982 Feb; 306(8):446-50. PubMed ID: 6276746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study.
    Munk-Jensen N; Pors Nielsen S; Obel EB; Bonne Eriksen P
    Br Med J (Clin Res Ed); 1988 Apr; 296(6630):1150-2. PubMed ID: 3132244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.